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Three sequential serum samples collected from each of 20 young children with a naturally acquired primary
rotavirus infection were assayed by the radioimmunoprecipitation technique for immunoglobulin G antibodies
to rotavirus structural and nonstructural proteins of the four major human rotavirus serotypes GI, PlA; G2,
POB; G3, P2; and G4, P2. Fourteen children were infected with a serotype Gi rotavirus strain and six children
were infected with a serotype G4 rotavirus strain. Sera were collected from each child in the acute and
convalescent periods postinfection and also approximately 4 months later. Serum immune responses to
rotavirus core antigens VP2 and VP3, to the major inner capsid antigen VP6, to nonstructural proteins NS35,
NS28, and NS26, and to the outer capsid neutralization antigen VP4 of all test strains were detected in the
majority of patients. These responses do not appear to be influenced by the G type or P type of the rotavirus
strain used in the reactions. Homologous responses to the main neutralization antigen VP7 were detected in
93% of patients with serotype Gl infections and 50%o of patients with serotype G4 infections. Heterologous VP7
responses were less frequently detected and were restricted to Gl, G3, and G4 serotype rotavirus strains. No
responses to VP7 of the serotype G2 rotavirus strain were detected in any patients. Heterotypic immune
responses to the neutralization antigens, at least following serotype Gl and G4 infections, therefore appear to
consist primarily of responses to VP4 rather than to VP7.
Rotaviruses are one of the leading causes of acute infantile
gastroenteritis throughout the world. The need for a safe and
effective vaccine strategy is recognized following epidemio-
logical studies in developing and developed countries. A
number of live animal rotavirus strains have already been
evaluated as human vaccine candidates in field trials (7, 17,
34). More recent approaches include the use of reassortant
viruses. These contain a single gene which codes for the
major neutralization antigen, VP7, from human virus sero-
types on an animal rotavirus background (11, 15, 23). Alter-
natively, the use of recombinant vaccines incorporating live
expression vectors or subunit vaccines of individual proteins
synthesized from DNA clones is recognized as another
possible approach to rotavirus vaccination (4), as is the use
of naturally attenuated neonatal rotavirus strains which
cause asymptomatic infection (3).
Rotavirus particles are composed of two capsid layers
which surround a core containing a genome of 11 double-
stranded RNA segments. These rotavirus genes code for
structural proteins found in virus particles and nonstructural
proteins found in infected cells but not present in mature
particles. The core and inner capsid of the rotavirus particle
are composed of structural proteins VP1 (125,000 Da), VP2
(94,000 Da), VP3 (88,000 Da), and VP6 (42,000 Da). The
remaining structural proteins VP4 (84,000 Da) and VP7
(34,000 Da), both of which induce antibodies with neutraliz-
ing activity and thus define serotype specificity, make up the
outer capsid layer of the rotavirus particle. Rotavirus strains
are now beginning to be classified into specific serotypes by
the use of single letters which represent these outer capsid
proteins. The letter P is used to denote the protease-sensitive
* Corresponding author.
protein VP4, and the letter G is used to denote the glyco-
protein VP7. Thus, each rotavirus strain is now assigned a
specific P type and G type on the basis of these neutralizing
antigens. The five nonstructural proteins of rotavirus are
thought to have a diverse array of roles in the replication
cycle of rotaviruses and are named according to their mo-
lecular masses, as follows: NS53 (53,000 Da), NS35 (35,000
Da), NS34 (34,000 Da), NS28 (28,000 Da), and NS26 (26,000
Da).
For a vaccine strategy to be effective, an understanding of
both the serum and mucosal immune responses which de-
velop to these structural and nonstructural rotavirus proteins
following infection is of major importance. In particular, an
understanding of the protein-specific immune response fol-
lowing naturally acquired primary infection is required.
Longitudinal studies of infection in young children have
found that such initial infections are likely to be the most
severe and may protect against the development of clinically
severe disease during reinfection (3, 27). The ultimate aim,
therefore, is to develop a broader understanding of the
immune response which follows these primary infections so
that an attempt can be made to reproduce similar immune
responses when using vaccine strains. Estimations of serum
immunoglobulin G (IgG) and IgM antibodies to rotavirus are
sensitive indicators of an immune response following severe
primary rotavirus gastroenteritis (14). Previously, animal
experiments have indicated that serum antibody levels gen-
erally cannot be correlated with protection (24, 30), although
a recent report by Ward et al. (36) has shown some correla-
tion of immunity with the magnitude of serum rotavirus IgG
titers in infected mice. Similarly, studies of human subjects
have sometimes indicated a correlation between preexisting
titers of neutralizing homotypic antibody in serum and
protection against rotavirus illness (6). We have previously
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investigated the IgG immune response to rotavirus structural
proteins in three sequential serum samples obtained from
each of 16 young children presenting with acute diarrhea
following a primary serotype Gl rotavirus infection (28).
Homotypic immune responses measured by Western blot-
ting (immunoblotting) were associated with serum IgG anti-
body to four rotavirus structural proteins: VP2, VP4, VP6,
and VP7. The timing and intensity of the IgG antibody
responses differed for each of these proteins but showed
similar trends in all patients. Antibody responses to VP2,
VP4, and VP7 were maximal in convalescent-phase sera,
while antibody to VP6 was usually first detected in acute-
phase sera and was found to persist for more than 4 months.
The technique of Western blotting permits analysis of
immunoglobulin class, but it has limitations in other re-
spects. The technique incorporates the use of denatured and
reduced antigenic proteins. Thus, it is possible to detect only
reactions of antibodies which bind to denaturation-resistant
linear epitopes of proteins which are not dependent on
conformation. Antibody reactions to denaturation-sensitive
epitopes are not detected. Intensity differences and detec-
tion of antibody responses may, therefore, partially reflect
the degree of conservation of antigenic epitopes within each
protein. The radioimmunoprecipitation (RIP) technique,
however, uses milder denaturation conditions and the viral
proteins are in a relatively native state when reacting with
serum antibody. In addition, the use of RIP allows the
detection of antibodies to nonstructural virus-associated
proteins found in infected cell preparations as well as those
to the viral structural proteins. Thus, a more comprehensive
analysis of the immune response to a broader range of
near-native rotavirus proteins can be achieved by this tech-
nique.
In the present study, the RIP technique was used to
evaluate the immune responses to rotavirus structural and
nonstructural proteins in the sera of young children with
either a serotype Gl or a serotype G4 primary rotavirus
infection. In addition, the antibody responses to rotavirus
proteins were also analyzed in the sera of two children who
had experienced a serotype G2 rotavirus infection. The
serum antibody responses to proteins of rotavirus strains
RV4 (serotype Gl, PlA), RV5 (serotype G2, P1B), RV3
(serotype G3, P2), and ST3 (serotype G4, P2) were exam-
ined, allowing analysis of homotypic and heterotypic anti-
body responses to the majority of group-specific, serotype-
specific (G and P types), and nonstructural proteins.
MATERIALS AND METHODS
Viruses. Local human rotavirus strains RV4 (Gl, PlA)
(subgroup II), RV5 (G2, P1B) (subgroup I), and RV3 (G3,
P2) (subgroup II) were isolated in our laboratory (1). The
ST3 human rotavirus (G4, P2) (subgroup II) was provided by
R. G. Wyatt, Bethesda, Md. These four rotavirus strains are
now considered to be standard strains representative of the
four most common G serotypes of rotavirus which infect
humans (9).
All viruses were routinely propagated in MA104 cells in
the presence of porcine trypsin type IX (10 ,ug/ml to activate
virus for 20 min at 37°C, 1 ,g/ml in maintenance medium;
Sigma Chemical Co., St. Louis, Mo.).
Patients. The majority of serum samples analyzed in the
present study were a subset of those collected for a previous
study in our department (14). The sera used were collected
from a total of 20 patients (14 males; 6 females) aged between
2 and 39 months (median age, 20.5 months) admitted to the
hospital with severe acute diarrhea caused by rotavirus. All
patients were considered to be experiencing a primary
rotavirus infection on the basis of an IgM-class rotavirus
antibody response measured in sera by an enzyme immuno-
assay (14). Fourteen children were infected with a serotype
Gl rotavirus strain and six children were infected with a
serotype G4 rotavirus strain. Some of these children have
been described in an earlier publication (28). All infections
were diagnosed upon admission of the child to the hospital,
and an enzyme immunoassay incorporating monoclonal an-
tibodies (8) was used to determine the group and serotype
antigens of the infecting rotavirus strain.
Acute-phase sera (collected 2 to 7 days postinfection;
median, 5.5 days), convalescent-phase sera (collected 26 to
42 days postinfection; median, 34 days), and follow-up sera
(collected 113 to 148 days postinfection; median, 121.5 days)
were obtained. These sets of three sequential serum samples
collected from each patient were assayed in the same exper-
iment by using identical RV4, RV5, RV3, or ST3 rotavirus
antigen preparations. All sera were stored at -70°C until
they were used in RIP assays, and the sera were used in the
assays either undiluted or at a 1:10 dilution.
In addition, a single serum sample was collected from each
of two children, aged 8 months and 3 years, who were
admitted to hospital with a serotype G2 rotavirus infection.
Sera were collected from these children at 1 or 3 months,
respectively, post-rotavirus infection and were reacted in
RIP assays by using RV4-, RV5-, or ST3-labeled rotavirus
proteins.
Hyperimmune sera. Seronegative rabbits were injected
subcutaneously three times with a cesium chloride-purified
preparation of rotavirus strain RV4, RV5, RV3, or ST3. The
rabbits were exsanguinated by cardiac puncture 14 days
after the final injection, and the antisera collected were
divided into aliquots and stored at -70°C until they were
used in RIP experiments.
Preparation of [3"S]methionine-labeled, rotavirus-infected
cell lysates. Confluent monolayers of MA104 cells grown in
35-mm petri dishes were infected with a 0.1-ml inoculum of
trypsin-activated virus at a multiplicity of 1 fluorescing
cell-forming unit per cell (RV4, RV5 and ST3) or 0.2 fluo-
rescing cell-forming unit per cell (RV3). Additional cell
monolayers were mock infected. After 1 h of adsorption at
37°C, the virus inoculum was removed and 1 ml of Dulbec-
co's modified Eagle's medium containing 1 ,g of trypsin per
ml and 2 ,g of actinomycin D per ml was added to each petri
dish. At 6 h postinfection (RV4, RV5, and ST3) or 12 h
postinfection (RV3), the medium was replaced with 0.1 ml of
methionine-free Eagle's minimum essential medium (Flow
Laboratories, Irvine, Scotland, United Kingdom) containing
150 mM excess NaCl, 1 Rg of trypsin per ml, 2 p,g of
actinomycin D per ml, and 100 ,Ci of [35S]methionine (>800
Ci/mmol; NEN Research Products) per ml for 1 h; this was
followed by replacement with 1.0 ml of Dulbecco's modified
Eagle's medium containing 150 mM excess NaCl, 1 ,g of
trypsin per ml, and 2 ,g of actinomycin D per ml for 30 min
at 37°C. The medium was then removed, and the cells were
washed twice with ice-cold phosphate-buffered saline (PBS)
and were then harvested by freezing at -70°C for a few
hours or overnight.
Cell lysates were prepared by adding 100 ,ul of lysis buffer
containing 0.8 M KCl, 10 mM Tris-hydrochloride (pH 7.8), 1
mM phenylmethylsulfonyl fluoride (PMSF), and 1% Triton
X-100 to each petri dish; this was followed by the addition of
400 ,ul of 10 mM Tris-hydrochloride (pH 7.8), 1 mM PMSF,
and 1% Triton X-100. The cell lysates were then centrifuged
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at 166,320 x g (Beckman rotor TLS 55) for 1 h at 4°C, and
the supernatants were collected and stored at -70°C until
they were used in immunoprecipitation experiments.
RIP. Mixtures of 25 ,ul of the viral lysate supernatant and
25 ,ul of undiluted human serum (or a 1:10 dilution if
insufficient serum was available) were incubated in Eppen-
dorf tubes overnight at 4°C. The immune complexes were
precipitated by the addition of 50 RI of Pansorbin cells, a
10% suspension of Staphylococcus aureus cells with a coat
of protein A in PBS (Calbiochem). After 1 h at room
temperature with frequent mixing, the precipitates were
collected by centrifugation at 5,000 rpm for 5 min in an
Eppendorf Microfuge and were then washed three times
with RIP wash buffer (0.05 M Tris [pH 7.4], 0.15 M NaCl, 1
mM EDTA, 0.25% bovine serum albumin, 0.05% Triton
X-100, and 0.02% NaN3). The adsorbed labeled viral pro-
teins were recovered by resuspending the pellets in 60 RI of
sample buffer (62.5 mM Tris-HCl [pH 6.8], 10% glycerol, 5%
P-mercaptoethanol, 2% sodium dodecyl sulfate [SDS],
0.01% bromophenol blue) and boiling for 4 min. The samples
were centrifuged at 10,000 rpm for 10 min in an Eppendorf
Microfuge, and the supernatants were applied to SDS-
polyacrylamide gels.
SDS-PAGE. Samples were analyzed by SDS-polyacryl-
amide gel electrophoresis (PAGE) and the discontinuous
Tris-glycine buffer system described by Laemmli (18). All
gels were 0.75-mm thick and consisted of a 4% acrylamide
stacking gel and a 10% acrylamide resolving gel run under
reducing conditions. Polypeptides were separated in the gel
by using a constant current of 30 mA for approximately 3 h
at room temperature. Lysates of rotavirus-infected cells
labeled with ["S]methionine were mixed with sample buffer,
boiled for 4 min, and applied to gels as migration reference
markers. Immediately after electrophoresis, the gels were
processed for fluorography by immersion directly in 1 M
sodium salicylate for 30 min at room temperature (5) and
were then dried and exposed to Kodak X-Omat AR-5 films at
-70°C for 7 days.
RESULTS
Identification of proteins. In each RIP assay, the profiles of
35S-labeled polypeptides of the RV4, RV5, RV3, or ST3
rotavirus strain and the corresponding mock-infected cellu-
lar proteins were examined. The labeled viral polypeptides
were identified by estimation of their molecular weights
relative to markers of known molecular weights and by
comparison with previously reported data. Only minor dif-
ferences in migration patterns were found for the viral
proteins of the four different rotavirus strains used in the
reactions.
Identification of the outer capsid protein VP4 and the two
trypsin cleavage products of VP4, VP5 and VP8, was con-
firmed following treatment of labeled viral proteins with
trypsin. Labeled rotavirus proteins were treated with 1.0,
2.0, 5.0, and 10.0 ,ug of trypsin per ml and were then reacted
with hyperimmune rabbit serum or a strongly reactive hu-
man serum in the RIP assay (Fig. 1). With increasing trypsin
concentrations, the amount of VP4 precipitated by serum
antibody was observed to decrease. At the same time, the
amount of precipitated VP5 remained constant, clearly dis-
tinguishing it from the NS53 protein which migrates through
the gel at a similar position. Reactions to a faintly labeled
band migrating at a molecular mass position of approxi-
mately 27,000 Da were also detected. This latter band
corresponded to the VP8 protein. Although the migration
1 2 3 4 5
VP1-*-t
VP2-
VP3=VP4S
VP5_ aNS531
VP6-Y
VP7-
NS35-
NS34-
VP8-
FIG. 1. SDS-PAGE analysis of [35S]methionine-labeled RV4
(Gl, P1A) proteins treated with increasing concentrations of trypsin
and immunoprecipitated with hyperimmune rabbit serum prepared
to the RV4 rotavirus strain. The hyperimmune rabbit serum was
used undiluted in the assay. The lanes show untreated RV4 proteins
(lane 1), and RV4 proteins treated with 1.0 ,ug of trypsin per ml (lane
2), 2.0 ,ug of trypsin per ml (lane 3), 5.0 pLg of trypsin per ml (lane 4),
and 10.0 ,ug of trypsin per ml (lane 5). The positions of the RV4
proteins, indicated in the left margin, were estimated by comparing
their migrations relative to those of protein standards in a 10%
acrylamide resolving gel.
positions of VP5 and VP8 could be identified following
treatment with trypsin, immune responses in patient sera to
these proteins could not be differentiated in routine RIP
assays.
Reproducibility of the RIP assay. As a test of reproducibil-
ity, the spectrum of viral polypeptides precipitated by a
hyperimmune rabbit serum prepared against the particular
rotavirus strain which had been labeled was examined in
each RIP assay (Fig. 2). Each hyperimmune serum sample
routinely precipitated bands corresponding to viral proteins
VP1, VP2, VP3, VP4, VP6, VP7, NS35, and NS34. The
number and intensities of the precipitated proteins were
similar between assays that incorporated the same rotavirus
strain.
Specificity of the RIP assay. The specificity of the RIP
assay was shown by incorporating aliquots of PBS in place
of serum samples in RIP assays with each rotavirus strain.
These control experiments were shown to nonspecifically
immunoprecipitate proteins VP1 and NS34 of each rotavirus
strain. Consequently, precipitation of these two proteins by
any test serum sample was excluded from the results.
Further specificity of the assay was demonstrated by
incorporating serum samples collected from five rotavirus-
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FIG. 2. SDS-PAGE analysis of [35S]methionine-labeled RV4
(G1, PKA), RV5 (G2, PMB), RV3 (G3, P2), and ST3 (G4, P2)
rotavirus proteins immunoprecipitated with hyperimmune rabbit
serum to the homologous labeled rotavirus strain. Lanes: 1, RV4
proteins precipitated with hyperimmune serum to RV4; 2, RV5
proteins precipitated with hyperimmune serum to RV5; 3, RV3
proteins precipitated with hyperimmune serum to RV3; and 4, ST3
proteins precipitated with hyperimmune serum to ST3.
seronegative children who were part of an earlier rotavirus
epidemiological study. The immune responses in two of
these serum samples are shown in Fig. 3. These sera were
reacted with labeled RV4 and RV5 proteins in the RIP assay
and were observed to precipitate up to two rotavirus pro-
teins: VP1 and NS34 when using RV4 and NS34 only when
using RV5. Both proteins were previously shown to be
nonspecifically precipitated in the absence of sera. No other
nonstructural proteins or rotavirus structural proteins were
precipitated by any of the five serum samples.
All patient sera and hyperimmune sera were also tested for
antibodies to mock-infected cellular proteins. Although a
_ _-VP6
:VP7
-NS 35
-NS 34
-NS 28
.i-NS 26
FIG. 3. SDS-PAGE analysis of [35S]methionine-labeled RV5
(G2, P1B) proteins immunoprecipitated with sera from two seroneg-
ative children and with a hyperimmune rabbit serum prepared
against the RV5 strain. All sera were used undiluted in the assay.
Lanes: 1 and 3, RV5 proteins precipitated with sera from seroneg-
ative children; 2 and 4, nonspecifically labeled cellular proteins
precipitated with the same sera from seronegative children; 5, RV5
proteins precipitated with a hyperimmune rabbit serum to RV5; 6,
labeled RV5 proteins.
number of cellular proteins were labeled with [35S]methio-
nine, even when using actinomycin D at a concentration of 2
,ug/ml, no reaction of these proteins with any undiluted or
1:10-diluted patient serum or hyperimmune rabbit serum
sample was evident in any RIP assay, indicating specific
precipitation of viral polypeptides only.
Occurrence of immune responses to rotavirus nonneutraliz-
ing group antigens (VP2, VP3, VP6). Immune responses to
two of the three proteins which make up rotavirus core
particles, VP2 and VP3, and to the major group-specific
polypeptide located on the inner capsid of virus particles,
VP6, were frequently detected in sera after infection with
either serotype Gl or serotype G4 rotavirus (Table 1). These
results represent the summation of the number of children
with a detectable response to each protein, regardless of the
timing of collection of the serum specimen in which the
responses were detected.
TABLE 1. Number of serotype Gl- and serotype G4-infected patients with detectable immune responses to group antigens VP2, VP3,
and VP6 of rotavirus strains RV4, RV5, RV3, and ST3
Serotype Gl-infected patients Serotype G4-infected patients
Rotavirus strain
(serotype) No. of % with detectable response to: No. of % with detectable response to:
patients VP2 VP3 VP6 patients VP2 VP3 VP6
RV4 (G1, P1A) 14 100 64 100 6 100 33 100
RV5 (G2, P1B) 9 100 67 100 6 67 17 100
RV3 (G3, P2) 14 100 79 100 6 100 50 100
ST3 (G4, P2) 13 100 92 100 6 100 100 100
VP1- O
VP2-
VP3-
VP4- _
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TABLE 2. Number of serotype Gl- and serotype G4-infected patients with detectable immune responses to neutralization antigens VP4
and VP7 of rotavirus strains RV4, RV5, RV3, and ST3
Serotype Gl-infected patients Serotype G4-infected patients
Rotavirus strain % with detectable % with detectable
(serotype) No. of response to: No. of response to:
patients patients
VP4 VP7 VP4 VP7
RV4 (G1, PlA) 14 100 93 6 100 33
RV5 (G2, P1B) 9 100 0 6 100 0
RV3 (G3, P2) 14 100 50 6 100 17
ST3 (G4, P2) 13 100 62 6 100 50
An antibody response to VP2 of all test strains was evident
in at least one serum sample collected from all patients with
a serotype Gl rotavirus infection. Patients with a serotype
G4 rotavirus infection also showed serum antibody re-
sponses to VP2 of all test strains, with the exception of two
patients in whom there was no response to VP2 of the
serotype G2 test strain.
In comparison with VP2, VP3 was precipitated less fre-
quently by serum antibody. After a serotype Gl rotavirus
infection, VP3 was immunoprecipitated in 64 to 92% of
patients, depending on the rotavirus strain used. Sera ob-
tained after a serotype G4 rotavirus infection immunopre-
cipitated VP3 in 17 to 100% of patients.
A serum antibody response to VP6 of all rotavirus strains
was detected in all patients examined, irrespective of the
infecting serotype.
Occurrence of immune responses to rotavirus neutralizing
antigens (VP4, VP7). The number of serum antibody re-
sponses to the two outer capsid proteins which induce
neutralizing antibody and which therefore define serotype
specificity, VP4 and VP7, is shown in Table 2.
A serum antibody response to VP4 of each test strain was
detected in at least one serum sample from all patients with
either a serotype Gl or serotype G4 rotavirus infection.
Antibody responses to the major neutralizing antigen VP7
were detected less frequently. In the group of patients with
a serotype Gl rotavirus infection, a serum immune response
was evident in 93% of patients to VP7 of RV4. In the
serotype 4-infected patients, 50% showed responses to VP7
of ST3. Responses to VP7 of noninfecting serotypes were
recorded in 17 to 62% of patients. An antibody response to
VP7 of the RV5 strain (serotype G2, P1B) was not detected
in any serum sample collected from any patient with either a
serotype Gl or a serotype G4 infection.
Occurrence of immune responses to nonstructural proteins
of rotavirus (NS35, NS28, NS26). Antibody responses to the
nonstructural proteins NS35, NS28, and NS26 of the four
rotavirus strains were detected in sera collected from a
proportion of patients with a serotype Gl rotavirus infection
or a serotype G4 rotavirus infection (Table 3).
An immune response to NS35 of each rotavirus strain was
detected in at least one serum sample collected postinfection
from all patients, irrespective of the serotype of the infecting
rotavirus strain.
Serum immune responses to the nonstructural protein
NS28 were also detected in the majority of patients tested.
Patients with a serotype Gl rotavirus infection showed
serum antibody to NS28 in 67 to 100% of cases, depending
on the rotavirus strain used. Patients with a serotype G4
rotavirus infection had antibody to NS28 of RV4, RV3, and
ST3 strains in 67 to 100% of cases. The NS28 protein of the
RV5 strain was not precipitated by any serum sample
collected from serotype G4-infected patients.
Responses to the third nonstructural protein, NS26, were
detected in 79, 22, 64, and 85% of serotype G1-infected
patients when we used the RV4, RV5, RV3, or ST3 strain,
respectively. Immune responses to NS26 were generally less
common in sera collected from patients with a serotype G4
rotavirus infection. As found for protein NS28, antibody to
NS26 of the RV5 strain was not detected in any serum
sample collected from serotype G4-infected patients.
An example of the spectrum of detected antibody re-
sponses to the structural and nonstructural proteins of the
four labeled human rotavirus preparations RV4, RV5, RV3,
and ST3 in one follow-up serum sample collected from a
serotype G1-infected patient is shown in Fig. 4.
Timing of serum immune responses to VP4 and VP7 follow-
ing serotype Gl or serotype G4 infection. The number of
immune responses to VP4 and VP7 detected in acute-phase
sera, convalescent-phase sera, and sera collected 4 months
postinfection in patients with either a serotype Gl or a
serotype G4 rotavirus infection is shown in Tables 4 and 5,
respectively. A similar timing in the appearance of antibody
to VP4 and VP7 was seen for both the serotype G1-infected
patients and the serotype G4-infected patients.
Antibody to VP4 was detected in a proportion of acute-
TABLE 3. Number of serotype Gl- and serotype G4-infected patients with detectable immune responses to nonstructural proteins NS35,
NS28, and NS26 of rotavirus strains RV4, RV5, RV3, and ST3
Serotype Gl-infected patients Serotype G4-infected patients
Rotavirus strain of % with detectable response to: No. of % with detectable response to:
patients NS35 NS28 NS26 patients NS35 NS28 NS26
RV4 (G1, P1A) 14 100 93 79 6 100 67 67
RV5 (G2, P1B) 9 100 67 22 6 100 0 0
RV3 (G3, P2) 14 100 86 64 6 100 100 50
ST3 (G4, P2) 13 100 100 85 6 100 100 67
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FIG. 4. SDS-PAGE analysis of [35S]methionine-labeled RV4
(Gl, PlA), RV5 (G2, P1B), RV3 (G3, P2), and ST3 (G4, P2)
rotavirus proteins immunoprecipitated with a follow-up serum sam-
ple collected 133 days postinfection from a serotype Gl-infected
patient. The serum was used undiluted in all assays. Lanes: 1, RV4
proteins; 2, RV5 proteins; 3, RV3 proteins; and 4, ST3 proteins.
phase sera (collected 2 to 7 days postinfection), although
only to a minimal intensity: 15 to 89% for serotype Gl-
infected patients and 33 to 67% for serotype G4-infected
patients, depending on the rotavirus strain used. However,
all convalescent-phase sera (collected 26 to 42 days postin-
TABLE 4. Number of immune responses to neutralizing antigen
VP4 of four rotavirus strains in serum samples collected from
patients with a serotype Gl or G4 rotavirus infection
No. of detectable immune responses to
VP4/total no. tested for the indicated
Infection with: Serum sample rotavirus strain (serotype):
RV4 RV5 RV3 ST3
(Gl, PlA) (G2, P1B) (G3, P2) (G4, P2)
Serotype Gl Acutea 10/14 8/9 5/14 2/13
Convb 14/14 9/9 14/14 13/13
Follow-upc 14/14 9/9 14/14 13/13
Serotype G4 Acute 4/6 2/6 3/6 2/6
Conv 3/3 3/3 3/3 3/3
Follow-up 6/6 6/6 6/6 6/6
a Acute-phase sera were collected 2 to 7 days postinfection.
b Convalescent (Conv)-phase sera were collected 26 to 42 days postinfec-
tion.
c Follow-up sera were collected 113 to 148 days postinfection.
TABLE 5. Number of immune responses to neutralizing antigen
VP7 of four rotavirus strains in serum samples collected from
patients with a serotype Gl or G4 rotavirus infection
No. of detectable immune responses to
VP7/total no. tested for the indicated
Infection with: Serum sample rotavirus strain (serotype):
RV4 RV5 RV3 ST3
(Gl, PlA) (G2, P1B) (G3, P2) (G4, P2)
Serotype Gl Acutea 0/14 0/9 0/14 0/13
Convb 8/14 0/9 5/14 5/13
Follow-upc 12/14 0/9 6/14 7/13
Serotype G4 Acute 2/6 0/6 0/6 1/6
Conv 2/3 0/3 1/3 2/3
Follow-up 1/6 0/6 1/6 3/6
a Acute-phase sera were collected 2 to 7 days postinfection.
b Convalescent (Conv)-phase sera were collected 26 to 42 days postinfec-
tion.
c Follow-up sera were collected 113 to 148 days postinfection.
fection) and follow-up sera (collected 113 to 148 days postin-
fection) contained antibody to VP4 of each rotavirus sero-
type.
In patients with a serotype Gl rotavirus infection, anti-
body responses to VP7 of RV4 (serotype Gl), RV3 (serotype
G3), and ST3 (serotype G4) were not evident in acute-phase
sera but appeared in 36 to 57% of convalescent-phase sera
and were detectable in 43 to 86% of follow-up sera. Re-
sponses to VP7 in patients with a serotype G4 rotavirus
infection were detectable in some acute-phase sera (33% to
VP7 of RV4 and 17% to VP7 of ST3). The number of
responses increased to 33 to 67% in convalescent-phase
sera, but then decreased to 17 to 50% in follow-up sera. No
antibody responses to VP7 of RV5 (serotype G2) were
evident in any serum sample collected from any child with
either a serotype Gl rotavirus infection or a serotype G4
rotavirus infection.
An example of the timing of appearance of immune
responses to the structural and nonstructural proteins of
rotavirus in the acute-phase, convalescent-phase, and fol-
low-up serum samples collected from one patient is illus-
trated in Fig. 5. For this example, we used a labeled RV3
antigen preparation and three serum samples collected from
a serotype Gl-infected patient.
Immune response of two patients with a serotype G2 infec-
tion. Serum samples collected from two children with a
serotype G2 rotavirus infection were incorporated in RIP
assays with labeled RV4, RV5, or ST3 rotavirus proteins.
There were insufficient sera for incorporation into the RIP
assay with labeled RV3 rotavirus proteins. Both patients
showed antibody responses to the major neutralizing antigen
VP7 of RV5 (serotype G2), in addition to other RV5 pro-
teins, VP2, VP3, VP4, VP6, NS35, NS28, and NS26. The
serum sample collected from one child (age, 8 months) at 1
month after a serotype G2 rotavirus infection also precipi-
tated the VP4 and VP7 neutralization antigens of the RV4
and ST3 strains, in addition to group antigens VP2, VP3,
and VP6 and the nonstructural protein NS35. The serum
sample collected from the second child (age, 3 years) at 3
months after a serotype G2 infection precipitated only the
major group antigen VP6 of the RV4 and ST3 rotavirus
strains.
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FIG. 5. SDS-PAGE analysis of [35S]methionine-labeled RV3
(G3, P2) proteins immunoprecipitated with acute-phase, convales-
cent-phase, and follow-up serum samples collected from a serotype
Gl-infected patient. Sera were used undiluted in the assay. Positions
of RV3 proteins were estimated by comparing their migrations
relative to those of standard proteins of known molecular weight.
Lanes: 1, acute-phase serum (7 days postinfection); 2, convalescent-
phase serum (39 days postinfection); and 3, follow-up serum (113
days postinfection).
DISCUSSION
RIP assays were developed to investigate the immune
response to the polypeptides of four human rotavirus strains
(representing four G types and three P types) following
naturally acquired rotavirus infection with serotypes Gl, G2,
or G4. The technique allows the analysis of the serum
immune response to a broad spectrum of individual rotavirus
proteins, including those carrying group-specific determi-
nants (VP2, VP3, VP6), those which induce antibodies with
neutralizing activity (VP4, VP7), and the nonstructural pro-
teins found in infected cells but not present in mature
particles (NS35, NS28, NS26). It was not possible to detect
specific antibody responses to the third core antigen of
rotavirus, VP1, or to the nonstructural protein NS34, since
these were obscured by nonspecific reactions.
Serum immune responses were detected to rotavirus core
antigens VP2 and VP3 and to the major inner capsid antigen
VP6 of all test strains, irrespective of the G type or the P
type, in the majority of patients. All three proteins carry
group determinants of rotavirus (10). Antibody to VP3 was
detected less frequently than was that to VP2 or VP6. This
result may reflect in part the relative amounts of each protein
found in rotavirus particles (19). VP6 is the major structural
protein in virus particles located on the outer surface of
single-shelled particles and makes up 51% of the total virion
protein. VP2 is the most abundant structural protein found in
core particles and the third most abundant protein in rotavi-
rus particles (-15% of the total virion protein). Both VP6
and VP2 have been shown to be highly immunogenic and
carry epitopes associated with subgroup specificity (16, 33).
In comparison with VP6 and VP2, VP3 is a minor structural
protein and makes up only approximately 0.5% of the total
virion protein.
Antibody responses to the outer-coat rotavirus proteins
VP4 and VP7, which are known to induce neutralizing
antibody, are of major interest. There is evidence that one or
both of these antibodies are protective against rotavirus
infection and/or disease in experimental animals (21, 22, 25,
26). Responses to VP4 of all test strains (including three
different P types) were detected in all patients regardless of
the infecting rotavirus serotype. Responses were frequently
rapid and were detectable 2 to 7 days postinfection in 15 to
89% of cases, although only to a minimal intensity. In
addition, responses to VP4 appeared to be persistent and
were evident in all patients up to 4 months postinfection. In
a previous work in which the investigators used the immu-
noblotting technique (28), anti-VP4 responses were detected
less frequently in children with a serotype 1 infection to a
homologous rotavirus strain. This result may be attributed to
the limitations of the immunoblotting technique, in which
only reactions of antibody to denaturation-resistant, linear
epitopes can be detected. Other previous studies have
shown antibody responses to VP4 to be a major component
of the immune response following either natural rotavirus
infection in children or following vaccination with an animal
rotavirus strain. In a study of sera collected from eight
children infected with a human subgroup I or II rotavirus,
Svensson et al. (31) detected antibody responses to the VP4
protein of a subgroup II rotavirus strain in all convalescent-
phase serum samples. Similarly, studies following vaccina-
tion of infants or adults with rotavirus strains RRV, RIT-
4237, or CJN (13, 29, 35) have found the VP4 protein to be a
strong immunogen that stimulates homologous and heterol-
ogous neutralizing antibody during infection of humans.
It was not possible to distinguish the serum immune
responses to the two trypsin cleavage products of VP4, VP5
and VP8. Responses to a protein band migrating at a position
analogous to that of both VP5 and NS53 were evident in at
least one serum sample from each patient studied but could
not be reliably differentiated from each other. From previ-
ously published work investigating the sequences of escape
mutants of VP4 selected with neutralizing monoclonal anti-
bodies (20, 32), it is known that VP5 contains predominantly
cross-reactive sites involved in heterologous neutralization.
These sites on VP5 have been found to be clustered in a
relatively limited area between amino acids 306 and 440.
Antibodies to these cross-reactive sites may in fact form the
basis of the homologous and heterologous serum immune
responses detected in all serotype Gl-infected and serotype
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G4-infected patients to VP4 of each of the four human
rotavirus strains used in the present study.
In the present study, homologous responses to VP7 ap-
peared after both serotype Gl and serotype G4 infections in
93 and 50% of patients, respectively. Heterologous VP7
responses were also detected but with less frequency and
were restricted to serotypes Gl, G3, and G4. The timing of
collection of serum specimens may have influenced the
detection of anti-VP7 antibody, particularly following sero-
type G4 infections. Only three convalescent-phase serum
samples were available from patients with a serotype G4
infection in the present study, and thus, anti-VP7 responses
may have been missed because of a lack of appropriate
serum specimens. Anti-VP7 responses were delayed when
compared with those to VP4 and were observed to be
maximal in intensity in convalescent-phase sera, as found in
a previous study with the same sera by an immunoblotting
technique (28). Thus, although the number of homologous
and heterologous anti-VP7 responses following serotype Gl
infection appeared to remain high beyond the convalescent
phase, the reaction intensities were noted to decrease in the
follow-up serum sample compared with that in the convales-
cent-phase serum sample. No responses to VP7 of RV5
(serotype G2, P1B) were detected in any patients. This
finding may relate to the fact that the VP7 protein of serotype
G2 rotavirus strains has been shown to have a lower degree
of sequence homology when compared with strains of sero-
types Gl, G3, and G4 than when these other serotypes are
compared with each other (12). This lack of heterotypic
responses to VP7 of serotype G2 implies that cross-protec-
tion between serotypes Gl, G3, and G4 and serotype G2 (if
it exists) could be mediated only via the VP4 protein.
One advantage of the RIP assay, in addition to the
detection of antibody to conformation-dependent epitopes,
is the detection of antibodies to the nonstructural rotavirus
proteins found in infected cells. Immune responses to three
of the five nonstructural proteins (NS35, NS28 and NS26)
were detected in the present study. Responses to NS35 of all
test strains were detected in at least one serum sample
collected from each patient examined. This nonstructural
protein has also been found to be relatively immunogenic
following natural infection in another study that used the RIP
technique (31). This finding is interesting in view of a report
suggesting that this protein (and not VP7) is the cellular
attachment protein (2), raising the question of whether this is
really a nonstructural protein. Responses to the other two
nonstructural proteins (NS28 and NS26) were relatively
common in children with a serotype Gl infection and slightly
less common in children with a serotype G4 infection. This
lack of detection of responses in the serotype G4-infected
children may again be due to insufficient appropriately timed
serum specimen collection.
In order to ascertain that the lack of detection of serum
responses to VP7 of the serotype G2 strain was not due to
errors inherent in the technique used, two children with a
serotype G2 rotavirus infection were also examined. A
strong homotypic immune response to both the VP4 and VP7
proteins of the RV5 (serotype G2) rotavirus strain was
detected in the sera collected from these two children. In
addition, one of these serotype G2-infected children showed
heterotypic responses to the VP4 and VP7 proteins of strains
RV4 (Gl, PlA) and ST3 (G4, P2). This heterotypic response
could possibly have been caused by a preexisting infection
with one (or both) of these serotypes. It was not known
whether the serotype G2 infections in these children were
primary infections, since only a single serum sample was
obtained from each child and they were aged 8 months and 3
years when admitted to the hospital. There were insufficient
sera to test for the presence of IgM antibodies.
Our results indicate that following naturally acquired
primary rotavirus infections, the serum antibody responses
detected by an RIP technique are to a wide array of rotavirus
proteins present in infected cells during replication of the
virus. Responses to core and inner capsid proteins, non-
structural proteins, and the neutralizing antigen VP4 are
similar for the three G-type infections studied (Gl, G2, G4)
and are not influenced by the G type or P type of the
rotavirus strain used in reactions. Heterotypic immune re-
sponses to the neutralization antigens, at least following
serotype Gl and G4 infections, appear to consist primarily of
responses to VP4 rather than to VP7. Anti-VP7 serum
responses, on the other hand, were detected more frequently
with homologous reactions than with heterologous reac-
tions, and no responses were detected to the VP7 antigen of
the human serotype G2 rotavirus strain RV5 in any serum
specimen studied. The relative importance of the VP4 pro-
tein as the dominant immunogen will ultimately depend on
the protective effect of antibody to VP4 against subsequent
rotavirus disease in humans.
ACKNOWLEDGMENTS
This work was supported by grants from the National Health and
Medical Research Council of Australia and the Royal Children's
Hospital Research Foundation.
REFERENCES
1. Albert, M. J., and R. F. Bishop. 1984. Cultivation of human
rotaviruses in cell culture. J. Med. Virol. 13:377-384.
2. Bass, D. M., E. R. Mackow, and H. B. Greenberg. 1990. NS35
and not VP7 is the soluble rotavirus protein which binds to
target cells. J. Virol. 64:322-330.
3. Bishop, R. F., G. L. Barnes, E. Cipriani, and J. S. Lund. 1983.
Clinical immunity after neonatal rotavirus infection. A prospec-
tive longitudinal study in young children. N. Engl. J. Med.
309:72-76.
4. Both, G. W., and P. A. Jennings. 1987. Gene cloning to study
viral antigens: prospects for novel influenza and rotavirus
vaccines. Prog. Vet. Microbiol. Immunol. 3:179-213.
5. Chamberlain, J. P. 1979. Fluorographic detection of radioactiv-
ity in polyacrylamide gels with the water-soluble fluor, sodium
salicylate. Anal. Biochem. 98:132-135.
6. Chiba, S., T. Yokoyama, S. Nakata, Y. Morita, T. Urasawa, K.
Taniguchi, S. Urasawa, and T. Nakao. 1986. Protective effect of
naturally acquired homotypic and heterotypic rotavirus antibod-
ies. Lancet ii:417-421.
7. Clark, H. F., F. E. Borian, L. M. Bell, K. Modesto, V. Gouvea,
and S. A. Plotkin. 1988. Protective effect ofWC3 vaccine against
rotavirus diarrhea in infants during a predominantly serotype 1
rotavirus season. J. Infect. Dis. 158:570-587.
8. Coulson, B. S., L. E. Unicomb, G. A. Pitson, and R. F. Bishop.
1987. Simple and specific enzyme immunoassay using mono-
clonal antibodies for serotyping human rotaviruses. J. Clin.
Microbiol. 25:509-515.
9. Estes, M. K. 1991. Rotaviruses and their replication, p. 619-642.
In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch,
J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fundamen-
tal virology, 2nd ed. Raven Press, New York.
10. Estes, M. K., and D. Y. Graham. 1985. Rotavirus antigens. Adv.
Exp. Med. Biol. 185:201-214.
11. Flores, J., I. Perez-Schael, M. Blanco, M. Vilar, D. Garcia, M.
Perez, N. Daoud, K. Midthun, and A. Z. Kapikian. 1989.
Reactions to and antigenicity of two human-rhesus rotavirus
reassortant vaccine candidates of serotypes 1 and 2 in Venezu-
elan infants. J. Clin. Microbiol. 27:512-518.
J. CLIN. MICROBIOL.
 o
n
 O
ctober 21, 2015 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
 
IMMUNE RESPONSES TO ROTAVIRUS PROTEINS BY RIP 385
12. Green, K. Y., K. Midthun, M. Gorziglia, Y. Hoshino, A. Z.
Kapikian, R. M. Chanock, and J. Flores. 1987. Comparison of
the amino acid sequences of the major neutralization protein of
four human rotavirus serotypes. Virology 161:153-159.
13. Green, K. Y., K. Taniguchi, E. R. Mackow, and A. Z. Kapikian.
1990. Homotypic and heterotypic epitope-specific antibody re-
sponses in adult and infant rotavirus vaccinees: implications for
vaccine development. J. Infect. Dis. 161:667-679.
14. Grimwood, K., J. C. S. Lund, B. S. Coulson, I. L. Hudson, R. F.
Bishop, and G. L. Barnes. 1988. Comparison of serum and
mucosal antibody responses following severe acute rotavirus
gastroenteritis in young children. J. Clin. Microbiol. 26:732-738.
15. Halsey, N. A., E. L. Anderson, S. D. Sears, M. Steinhoff, M.
Wilson, R. B. Belshe, K. Midthun, A. Z. Kapikian, B. Burns, and
M. L. Clements. 1988. Human-rhesus reassortant rotavirus
vaccines: safety and immunogenicity in adults, infants, and
children. J. Infect. Dis. 158:1261-1267.
16. Kapikian, A. Z., W. L. Cline, H. B. Greenberg, R. G. Wyatt,
A. R. Kalica, C. E. Banks, H. D. James, J. Flores, and R. M.
Chanock. 1981. Antigenic characterization of human and animal
rotaviruses by immune adherence hemagglutination assay
(IAHA): evidence for distinctness of IAHA and neutralization
antigens. Infect. Immun. 33:415-425.
17. Kapikian, A. Z., K. Midthun, Y. Hoshino, J. Flores, R. G.
Wyatt, R. I. Glass, J. Askaa, 0. Nakagomi, T. Nakagomi, R. M.
Chanock, M. M. Levine, M. L. Clements, R. Dolin, P. F. Wright,
R. B. Belshe, E. L. Anderson, and L. Potash. 1985. Rhesus
rotavirus: a candidate vaccine for prevention of human rotavi-
rus disease, p. 357-367. In R. A. Lerner, R. M. Chanock, and F.
Brown (ed.), Vaccines 85. Molecular and chemical basis of
resistance to parasitic, bacterial, and viral diseases. Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y.
18. Laemmli, U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227:680-685.
19. Liu, M., P. A. Offit, and M. K. Estes. 1988. Identification of the
simian rotavirus SAll genome segment 3 product. Virology
163:26-32.
20. Mackow, E. R., R. D. Shaw, S. M. Matsui, P. T. Vo, M. N.
Dang, and H. B. Greenberg. 1988. Characterization of the rhesus
rotavirus VP3 gene: location of amino acids involved in homol-
ogous and heterologous rotavirus neutralization and identifica-
tion of a putative fusion region. Proc. Natl. Acad. Sci. USA
85:645-649.
21. Matsui, S. M., E. R. Mackow, and H. B. Greenberg. 1989.
Molecular determinants of rotavirus neutralization and protec-
tion. Adv. Virus Res. 36:181-214.
22. Matsui, S. M., P. A. Offit, P. T. Vo, E. R. Mackow, D. A.
Benfield, R. D. Shaw, L. Padilla-Noriega, and H. B. Greenberg.
1989. Passive protection against rotavirus-induced diarrhea by
monoclonal antibodies to the heterotypic neutralization domain
of VP7 and the VP8 fragment of VP4. J. Clin. Microbiol.
27:780-782.
23. Midthun, K., H. B. Greenberg, Y. Hoshino, A. Z. Kapikian,
R. G. Wyatt, and R. M. Chanock. 1985. Reassortant rotaviruses
as potential live rotavirus vaccine candidates. J. Virol. 53:949-
954.
24. Offit, P. A., and H. F. Clark. 1985. Protection against rotavirus-
induced gastroenteritis in a murine model by passively acquired
gastrointestinal but not circulating antibodies. J. Virol. 54:58-
64.
25. Offit, P. A., H. F. Clark, G. Blavat, and H. B. Greenberg. 1986.
Reassortant rotaviruses containing structural proteins VP3 and
VP7 from different parents induce antibodies protective against
each parental serotype. J. Virol. 60:491-496.
26. Offit, P. A., R. D. Shaw, and H. B. Greenberg. 1986. Passive
protection against rotavirus-induced diarrhea by monoclonal
antibodies to surface proteins VP3 and VP7. J. Virol. 58:700-
703.
27. Reves, R. R., M. Mohassin, K. Midthun, A. Z. Kapikian, T.
Naguib, A. M. Zaki, and H. L. DuPont. 1989. An observational
study of naturally acquired immunity to rotaviral diarrhea in a
cohort of 363 Egyptian children. Calculation of risk for second
episodes using age-specific person-years of observation. Am. J.
Epidemiol. 130:981-988.
28. Richardson, S. C., and R. F. Bishop. 1990. Homotypic serum
antibody responses to rotavirus proteins following primary
infection of young children with serotype 1 rotavirus. J. Clin.
Microbiol. 28:1891-1897.
29. Shaw, R. D., K. J. Fong, G. A. Losonsky, M. M. Levine, Y.
Maldonado, R. Yolken, J. Flores, A. Z. Kapildan, P. T. Vo, and
H. B. Greenberg. 1987. Epitope-specific immune responses to
rotavirus vaccination. Gastroenterology 93:941-950.
30. Snodgrass, D. R., and P. W. Wells. 1978. Passive immunity in
rotaviral infections. J. Am. Vet. Med. Assoc. 173:565-568.
31. Svensson, L., H. Sheshberadaran, S. Vene, E. Norrby, M.
Grandien, and G. Wadell. 1987. Serum antibody responses to
individual viral polypeptides in human rotavirus infections. J.
Gen. Virol. 68:643-651.
32. Taniguchi, K., W. L. Maloy, K. Nishikawa, K. Y. Green, Y.
Hoshino, S. Urasawa, A. Z. Kapikian, R. M. Chanock, and M.
Gorziglia. 1988. Identification of cross-reactive and serotype-
specific neutralization epitopes on VP3 of human rotavirus. J.
Virol. 62:2421-2426.
33. Taniguchi, K., T. Urasawa, and S. Urasawa. 1986. Reactivity
patterns to human rotavirus strains of a monoclonal antibody
against VP2, a component of the inner capsid of rotavirus. Arch.
Virol. 87:135-141.
34. Vesikari, T., E. Isolauri, E. D'Hondt, A. Delem, F. E. Andre,
and G. Zissis. 1984. Protection of infants against rotavirus
diarrhoea by RIT 4237 attenuated bovine rotavirus strain vac-
cine. Lancet i:977-980.
35. Ward, R. L., D. R. Knowlton, G. M. Schiff, Y. Hoshino, and
H. B. Greenberg. 1988. Relative concentrations of serum neu-
tralizing antibody to VP3 and VP7 proteins in adults infected
with a human rotavirus. J. Virol. 62:1543-1549.
36. Ward, R. L., M. M. McNeal, and J. F. Sheridan. 1992. Evidence
that active protection following oral immunization of mice with
live rotavirus is not dependent on neutralizing antibody. Virol-
ogy 188:57-66.
VOL. 31, 1993
 o
n
 O
ctober 21, 2015 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
 
